Publications

Oct 17, 2025
Publications
GEODE: an in silico tool that translates in vitro to in vivo predictions of tuberculosis antibiotic combination efficacy
Maral Budak, Mariana Pereira Moraes, Talia Greenstein, Pauline Maiello , H Jacob Borish, Harris B Chishti, Kara Kracinovsky, Mark Rodgers, Jaime Tomko, Philana Ling Lin, JoAnne L Flynn, Bree B Aldridge, Denise Kirschner
Front Pharmacol. 2025 Oct 17:16:1639673
PMID: 41181601 | PMCID: PMC12575316 | DOI: 10.3389/fphar.2025.1639673

Sep 26, 2025
Publications
Human Cases of Carbapenemase-Producing Escherichia coli Linked to Spread Between Animals and the Environment in a Veterinary Facility -Massachusetts, USA, 2023
Ian M DeStefano, Claire L Fellman, Paula M Snippes Vagnone, Melissa A Cumming, Jennifer L Dale, Abbey Ruhland, Jaclyn Dietrich, Catherine M Brown, Esther Fortes, Nicolas N Epie, Amanda Beaudoin, Katherine Janiszewski, Jessica Leaf, Shira Doron, Matthew Doucette, Stephen D Cole
Clin Infect Dis. 2025 Sep 26:ciaf541.

Jan 27, 2020
Publications
Colistin-resistant Escherichia coli carrying mcr-1 in food, water, hand rinse, and healthy human gut in Bangladesh
Publications Keywords ← Previous postNext post → Posted by Mao 24 Share Copied!

Feb 17, 2026
Publications
Promises and Challenges of the Type Three Secretion System Injectisome as an Antivirulence Target
Antibiotic resistance is a major public health threat that has stimulated the scientific community to search for nontraditional therapeutic targets. Because virulence, but not the growth, of many Gram-negative bacterial pathogens depends on the multicomponent type three secretion system injectisome (T3SSi), the T3SSi has been an attractive target for identifying small molecules, peptides, and monoclonal antibodies that inhibit its function to render the pathogen avirulent.

Jan 17, 2026
Publications
Parenterally Administered Vancomycin in 29 Dogs and 7 Cats (2003-2017)
Ian M. DeStefano Annie S. Wayne Elizabeth A. Rozanski Jonathan M. Babyak

Jan 17, 2026
Publications
Prophage induction, but not production of phage particles, is required for lethal disease in a microbiome-replete murine model of enterohemorrhagic E. coli infection.
Enterohemorrhagic Escherichia coli (EHEC) colonize intestinal epithelium by generating characteristic attaching and effacing (AE) lesions. They are lysogenized by prophage that encode Shiga toxin 2 (Stx2), which is responsible for severe clinical manifestations.

Jan 17, 2026
Publications
Partial Oral Therapy for Osteomyelitis and Endocarditis – Is It Time?
Antimicrobial resistance threatens health and global security, with an estimated 162,000 deaths per year in the United States caused by multidrug-resistant infections

Nov 14, 2018
Publications
Synthesis of the Non-Reducing Hexasaccharide Fragment of Saccharomicin B
ACS Publications, Organic Letters, 2018 Nov 14. doi: 10.1021/acs.orglett.8b03333

Nov 17, 2026
Publications
An Experimental Pipeline for Initial Characterization of Bacterial Type III Secretion System Inhibitor Mode of Action Using Enteropathogenic Yersinia
Dozens of Gram negative pathogens use one or more type III secretion systems (T3SS) to disarm host defenses or occupy a beneficial niche during infection of a host organism.

Oct 12, 2018
Publications
Good Studies Evaluate the Disease While Great Studies Evaluate the Patient: Development and Application of a Desirability of Outcome Ranking Endpoint for Staphylococcus aureus Bloodstream Infection
Sarah B Doernberg, Thuy Tien Tram Tran, Steven Y C Tong, Mical Paul, Dafna Yahav, Joshua S Davis, Leonard Leibovici, Helen W Boucher, G Ralph Corey, Sara E Cosgrove, Henry F Chambers, Vance G Fowler, Scott R Evans, Thomas L Holland,

Oct 31, 2018
Publications
The PARE Project: A Short Course-Based Research Project for National Surveillance of Antibiotic-Resistant Microbes in Environmental Samples
Course-based research experiences (CREs) have been proposed as an inclusive model to expose all students, including those at institutions without a strong research infrastructure, to research at an early stage.

Oct 17, 2026
Publications
The landscape of intrinsic and evolved fluoroquinolone resistance in Acinetobacter baumannii includes suppression of drug-induced prophage replication
The emergence of fluoroquinolone resistance in nosocomial pathogens has restricted the clinical efficacy of this antibiotic class. In Acinetobacter baumannii, the majority of clinical isolates now show high level resistance due to mutations in gyrA (DNA gyrase) and parC (Topo IV).

